Quick Answer
Immuneering Corp reported Stockholders Equity of $218.48 million for the year ending 2025.
- Immuneering Corp showed an increase of +427.9% in Stockholders Equity from 2024 to 2025.
- This data is from Immuneering Corp's annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$9.46 million | Q2 2020: -$12.77 million | Q3 2020: -$16.86 million | Q1 2021: -$28.53 million | Q2 2021: -$35.19 million | Q3 2021: $158.29 million | Q1 2022: $144.06 million | Q2 2022: $133.59 million | Q3 2022: $121.89 million | Q1 2023: $97.79 million | Q2 2023: $115.10 million | Q3 2023: $104.02 million | Q1 2024: $78.72 million | Q2 2024: $66.31 million | Q3 2024: $57.72 million | Q1 2025: $41.84 million | Q2 2025: $28.94 million | Q3 2025: $227.98 million.
- Over the full 7 years of available data (2019 to 2025), Immuneering Corp's Stockholders Equity has grown by 3,446.7%.
- Historical annual values: Fiscal year 2025: $218.48 million | Fiscal year 2024: $41.39 million | Fiscal year 2023: $90.58 million | Fiscal year 2022: $109.85 million | Fiscal year 2021: $155.98 million | Fiscal year 2020: -$22.48 million | Fiscal year 2019: -$6.53 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: